PT3551166T - Fenitoína tópica para utilização no tratamento de dor neuropática periférica - Google Patents

Fenitoína tópica para utilização no tratamento de dor neuropática periférica

Info

Publication number
PT3551166T
PT3551166T PT178179271T PT17817927T PT3551166T PT 3551166 T PT3551166 T PT 3551166T PT 178179271 T PT178179271 T PT 178179271T PT 17817927 T PT17817927 T PT 17817927T PT 3551166 T PT3551166 T PT 3551166T
Authority
PT
Portugal
Prior art keywords
treatment
neuropathic pain
peripheral neuropathic
phenytoin
topical
Prior art date
Application number
PT178179271T
Other languages
English (en)
Original Assignee
Topical Innovations B V
Keppel Hesselink Jan Marius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topical Innovations B V, Keppel Hesselink Jan Marius filed Critical Topical Innovations B V
Publication of PT3551166T publication Critical patent/PT3551166T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT178179271T 2016-12-06 2017-12-06 Fenitoína tópica para utilização no tratamento de dor neuropática periférica PT3551166T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2017931 2016-12-06

Publications (1)

Publication Number Publication Date
PT3551166T true PT3551166T (pt) 2024-10-28

Family

ID=57796933

Family Applications (1)

Application Number Title Priority Date Filing Date
PT178179271T PT3551166T (pt) 2016-12-06 2017-12-06 Fenitoína tópica para utilização no tratamento de dor neuropática periférica

Country Status (21)

Country Link
US (1) US11285099B2 (pt)
EP (1) EP3551166B1 (pt)
JP (1) JP7264813B2 (pt)
CN (1) CN110248644A (pt)
AU (1) AU2017371467B2 (pt)
BR (1) BR112019011743A2 (pt)
CA (1) CA3046055A1 (pt)
CL (1) CL2019001550A1 (pt)
DK (1) DK3551166T3 (pt)
DO (1) DOP2019000156A (pt)
EA (1) EA201991341A1 (pt)
ES (1) ES2991885T3 (pt)
FI (1) FI3551166T3 (pt)
IL (1) IL267114B2 (pt)
MA (1) MA51978A (pt)
MX (1) MX2019006640A (pt)
PH (1) PH12019550093A1 (pt)
PT (1) PT3551166T (pt)
UA (1) UA125040C2 (pt)
WO (1) WO2018106107A1 (pt)
ZA (1) ZA201906473B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005034B2 (en) 2017-04-25 2024-06-11 Algotherapeutix Topical pharmaceutical composition comprising at least amitriptyline, for the treatment of peripheral neuropathic pain
FR3095589B1 (fr) * 2019-05-02 2021-05-07 Air Liquide Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients recevant des médicaments de plusieurs classes thérapeutiques
PL4025183T3 (pl) 2019-09-02 2025-09-22 Syddansk Universitet Induktory P-gp do stosowania w ochronie przed skutkami ubocznymi chemioterapii takimi jak neuropatia obwodowa wywołana chemioterapią (CIPN) oraz utrata włosów
FR3108841B1 (fr) 2020-04-06 2023-11-03 Algotherapeutix Composition pharmaceutique topique sous forme de gel aqueux comprenant au moins de l’amitriptyline
CN114681340A (zh) * 2022-04-13 2022-07-01 肌赋萃生物科技(上海)有限公司 一种含有脂质包裹稳定技术的脂质屏障修复护肤品及其制备方法
WO2024120461A1 (zh) * 2022-12-09 2024-06-13 荣昌生物制药(烟台)股份有限公司 Cyp3a4/5诱导剂在治疗或缓解周围神经病变中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571521A (en) 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
JP3031973B2 (ja) 1990-08-16 2000-04-10 富士レビオ株式会社 フェニトイン誘導体
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
CN1046199C (zh) * 1994-12-13 1999-11-10 凌吉安 复方消炎止痛霜剂
DE69733081T2 (de) 1996-08-23 2006-05-11 Endo Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
WO2001000191A2 (en) * 1999-06-23 2001-01-04 Warner-Lambert Company Use of fosphenytion for the treatment of acute neuropathic pain
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
HUP0304078A2 (hu) * 2001-05-15 2004-04-28 Warner-Lambert Co. Llc Tömörítési eljárás nátrium-fenitoin gyógyszerkészítmény előállítására
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
CA2574555A1 (en) 2004-08-03 2006-02-09 Royal College Of Surgeons In Ireland Phenytoin formulations, and uses thereof in wound healing
US20060034910A1 (en) * 2004-08-09 2006-02-16 Sanjay Patel Pharmaceutical composition for extended release of phenytoin sodium
CN101069692B (zh) * 2006-05-08 2011-04-20 范敏华 含积雪草总甙的药物制剂及其制备方法
WO2008079727A2 (en) 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
US20110275137A1 (en) * 2008-04-14 2011-11-10 Seikagaku Corporation Improving agent for neuropathic pain
CA2729346A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
AU2009296457A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
KR101271219B1 (ko) * 2011-01-27 2013-06-07 광주과학기술원 신규한 하이단토인 유도체 및 이의 용도
WO2012176668A1 (ja) 2011-06-20 2012-12-27 久光製薬株式会社 リドカイン含有パップ剤
US20130184351A1 (en) 2011-12-21 2013-07-18 Jar Laboratories Lidocaine patch and methods of use thereof
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US20160303203A1 (en) * 2013-12-09 2016-10-20 Keshav Malshe Compositions and methods for the treatment of wounds
CN106075556A (zh) 2016-06-02 2016-11-09 四川奎星医用高分子制品有限责任公司 含有促进伤口愈合药物的医用复合壳聚糖凝胶

Also Published As

Publication number Publication date
CN110248644A (zh) 2019-09-17
CA3046055A1 (en) 2018-06-14
IL267114B2 (en) 2024-08-01
AU2017371467B2 (en) 2023-06-01
CL2019001550A1 (es) 2020-02-28
ZA201906473B (en) 2020-07-29
IL267114A (en) 2019-08-29
AU2017371467A1 (en) 2019-07-25
US20200276106A1 (en) 2020-09-03
DK3551166T3 (da) 2024-10-21
IL267114B1 (en) 2024-04-01
US11285099B2 (en) 2022-03-29
FI3551166T3 (fi) 2024-10-04
JP2020500915A (ja) 2020-01-16
EA201991341A1 (ru) 2019-12-30
UA125040C2 (uk) 2021-12-29
MA51978A (fr) 2021-01-20
BR112019011743A2 (pt) 2019-10-22
MX2019006640A (es) 2019-08-01
DOP2019000156A (es) 2020-07-15
WO2018106107A1 (en) 2018-06-14
JP7264813B2 (ja) 2023-04-25
EP3551166B1 (en) 2024-08-21
ES2991885T3 (es) 2024-12-05
EP3551166A1 (en) 2019-10-16
PH12019550093A1 (en) 2020-02-10

Similar Documents

Publication Publication Date Title
IL290150A (en) Compounds and methods for treating chronic pain
ZA201906473B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
IL266198A (en) Liposomal formulation for use in cancer treatment
IL270978B (en) Grape skin for use in the treatment of dysbiosis
ZA201704726B (en) Peptides and their use in the treatment of skin
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
PL3423060T3 (pl) Imatynib do stosowania w leczeniu udaru mózgu
IL246855A0 (en) Materials for use in the treatment of retinitis
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
SG11201705524SA (en) Compositions and methods for the treatment of inflammation and pain
IL273863A (en) Hemorrhoid treatment device
IL269894B (en) Small organic molecules for use in the treatment of neuroinflammatory diseases
GB2568132B (en) High-performance hair treatment agents with increased care effect
PL3621614T3 (pl) Lotion zawierający tazaroten do stosowania miejscowego w leczeniu trądziku
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201423268D0 (en) The combination for acne cleansing and skin metabolism improving
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
PT3010543T (pt) Agentes terapêuticos para utilização na profilaxia e/ou tratamento de distúrbios de movimento hiperquinéticos
PL3478260T3 (pl) Kompozycja do pielęgnacji skóry i jej zastosowanie
HK40015081B (en) Topical phenytoin for use in the treatment of peripheral neuropathic pain
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
HK40027056A (en) Grape skin for use in the treatment of dysbiosis
GB201718111D0 (en) Skin treatment device
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido